K cell therapy with Elotuzumab following autologous stem cell transplantation for newly diagnosed multiple myeloma patients
Not Applicable
Recruiting
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000033128
- Lead Sponsor
- Department of Hematology, Tokyo Women's University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who were previously transplanted. 2. Failed to obtain more than 2x10E6/kg of CD34+ cells 3. Patients who are not harvest or transplant eligible due to cardiac or pulmonary disorder. AST,ALT, Total bilirubin>2.5xlower limit, serum Cr>=2.0mg/dl 4. Pregnant or breast feeding 5. With uncontrollable active infection 6. Patients who have severe allergy 7. HIV positive, HBV antigen positive or HBV-DNA positive by PCR patients 8. Without written informed consent 9. By medical reasons, patients who arejudged as inappropriate by doctors or researchers. 10. Patient with other active malignancies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method